Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

Abstract Background Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We discovered that activation of the non-rec...

Full description

Bibliographic Details
Main Authors: Katie K. Crean-Tate, Chad Braley, Goutam Dey, Emily Esakov, Caner Saygin, Alexandria Trestan, Daniel J. Silver, Soumya M. Turaga, Elizabeth V. Connor, Robert DeBernardo, Chad M. Michener, Peter G. Rose, Justin Lathia, Ofer Reizes
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Journal of Ovarian Research
Subjects:
Ovarian cancer
Platinum resistance
LCK inhibitor
Chemosensitization
Online Access:https://doi.org/10.1186/s13048-021-00797-x

Internet

https://doi.org/10.1186/s13048-021-00797-x

Similar Items